Activity-based protein profiling: Applications to biomarker discovery, in vivo imaging and drug discovery

American Journal of PharmacoGenomics

Volumn 4, Issue 6, 2004, Pages 371-381

  Berger, Alicia B ^a   Vitorino, Phillip M ^a   Bogyo, Matthew ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYSTEINE PROTEINASE; ILOMASTAT; METALLOPROTEINASE; NEW DRUG; PHOSPHATASE; PROTEIN INHIBITOR; SERINE PROTEINASE; SMALL MOLECULE INHIBITOR; THREONINE PROTEINASE; UNCLASSIFIED DRUG;

BINDING AFFINITY; DISEASE MARKER; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVITY; ENZYME BINDING; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE SEQUENCE; GENOMICS; IN VIVO STUDY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN ISOLATION; PROTEIN MODIFICATION; PROTEIN PROCESSING; PROTEIN PURIFICATION; REVIEW;

ANIMALS; BIOLOGICAL MARKERS; DRUG DESIGN; HUMANS; PROTEIN ARRAY ANALYSIS; PROTEINS; PROTEOME;

EID: 11144245547     PISSN: 11752203     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129785-200404060-00004     Document Type: Review

References (73)

1. Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome. Science 2001 Feb 16; 291: 1304-51
2. Corthals GL, Wasinger VC, Hochstrasser DF, et al. The dynamic range of protein expression: a challenge for proteomic research. Electrophoresis 2000 Apr; 21: 1104-15
3. Patton WF. A thousand points of light: the application of fluorescence detection technologies to two-dimensional gel electrophoresis and proteomics. Electrophoresis 2000 Apr; 21: 1123-44
4. Santoni V, Molloy M, Rabilloud T. Membrane proteins and proteomics: un amour impossible? Electrophoresis 2000 Apr; 21: 1054-70
5. Gygi SP, Corthals GL, Zhang Y, et al. Evaluation of two-dimensional gel electrophoresis-based proteome analysis technology. Proc Natl Acad Sci U S A 2000 Aug 15; 97: 9390-5
6. Gygi SP, Rist B, Gerber SA, et al. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat Biotechnol 1999 Oct; 17: 994-9
7. Zhou H, Ranish JA, Watts JD, et al. Quantitative proteome analysis by solid-phase isotope tagging and mass spectrometry. Nat Biotechnol 2002 May; 20: 512-5
8. Goshe MB, Smith RD. Stable isotope-coded proteomic mass spectrometry. Curr Opin Biotechnol 2003 Feb; 14: 101-9
9. Petricoin EF, Liotta LA. SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer. Curr Opin Biotechnol 2004 Feb; 15: 24-30
10. Jeffery DA, Bogyo M. Chemical proteomics and its application to drag discovery. Curr Opin Biotechnol 2003 Feb; 14: 87-95
11. Speers AE, Cravatt BF. Chemical strategies for activity-based proteomics. Chembiochem 2004 Jan 3; 5: 41-7
12. Adam GC, Cravatt BF, Sorensen EJ. Profiling the specific reactivity of the proteome with non-directed activity-based probes. Chem Biol 2001 Jan; 8: 81-95
13. Adam GC, Sorensen EJ, Cravatt BF. Chemical strategies for functional proteomics. Mol Cell Proteomics 2002 Oct; 1: 781-90
14. Greenbaum D, Medzihradszky KF, Burlingame A, et al. Epoxide electrophiles as activity-dependent cysteine protease profiling and discovery tools. Chem Biol 2000 Aug; 7: 569-81
15. Greenbaum D, Baruch A, Hayrapetian L, et al. Chemical approaches for functionally probing the proteome. Mol Cell Proteomics 2002 Jan; 1: 60-8
16. 125I]iodotyrosylalanyldiazomethane as a probe for active cysteine proteinases in human tissues. Biochem J 1989 Nov 1; 263: 945-9
17. Shi GP, Munger JS, Meara JP, et al. Molecular cloning and expression of human alveolar macrophage cathepsin S, an elastinolytic cysteine protease. J Biol Chem 1992; 267 (11): 7258-62
18. Bogyo M, Verhelst S, Bellingard-Dubouchaud V, et al. Selective targeting of lysosomal cysteine proteases with radiolabeled electrophilic substrate analogs. Chem Biol 2000 Jan; 7: 27-38
19. Schaschke N, Assfalg-Machleidt I, Lassleben T, et al. Epoxysuccinyl peptide-derived affinity labels for cathepsin B. FEBS Lett 2000; 482 (1-2): 91-6
20. Borodovsky A, Kessler BM, Casagrande R, et al. A novel active site-directed probe specific for deubiquitylating enzymes reveals proteasome association of USP14. EMBO J 2001; 20 (18): 5187-96
21. Mikolajczyk J, Boatright KM, Stennicke HR, et al. Sequential autolytic processing activates the zymogen of Arg-gingipain. J Biol Chem 2003; 278 (12): 10458-64
22. Liu Y, Patricelli MP, Cravatt BF. Activity-based protein profiling: the serine hydrolases. Proc Natl Acad Sci U S A 1999 Dec 21; 96: 14694-9
23. Patricelli MP, Giang DK, Stamp LM, et al. Direct visualization of serine hydrolase activities in complex proteomes using fluorescent active site-directed probes. Proteomics 2001 Sep; 1: 1067-71
24. Kidd D, Liu Y, Cravatt BF. Profiling serine hydrolase activities in complex proteomes. Biochemistry 2001; 40 (13): 4005-15
25. Meng L, Kwok BH, Sin N, et al. Eponemycin exerts its antitumor effect through the inhibition of proteasome function. Cancer Res 1999; 59 (12): 2798-801
26. Saghatelian A, Jessani N, Joseph A, et al. Activity-based probes for the proteomic profiling of metalloproteases. Proc Natl Acad Sci U S A 2004 Jul 6; 101: 10000-5
27. Kumar S, Zhou B, Liang F, et al. Activity-based probes for protein tyrosine phosphatases. Proc Natl Acad Sci U S A 2004 May 25; 101: 7943-8
28. Zhu Q, Huang X, Chen GYJ, et al. Activity based fluorescent probes that target phosphatases. Tetrahedron Lett 2003; 44: 2669-72
29. Adam GC, Sorensen EJ, Cravatt BF. Proteomic profiling of mechanistically distinct enzyme classes using a common chemotype. Nat Biotechnol 2002 Aug; 20: 805-9
30. Thornberry NA, Peterson EP, Zhao JJ, et al. Inactivation of interleukin-1 beta converting enzyme by peptide (acyloxy)methyl ketones. Biochemistry 1994 Apr 5; (33): 3934-40
31. Hawthorne S, Hamilton R, Walker BJ, et al. Utilization of biotinylated diphenyl phosphonates for disclosure of serine proteases. Anal Biochem 2004 Mar 15; 326: 273-5
32. Zhu Q, Girish A, Chattopadhaya S, et al. Developing novel activity-based fluorescent probes that target different classes of proteases. Chem Commun (Camb) 2004 Jul; 7 (13): 1512-3
33. Greenbaum DC, Arnold WD, Lu F, et al. Small molecule affinity fingerprinting: a tool for enzyme family subclassification, target identification, and inhibitor design. Chem Biol 2002 Oct; 9: 1085-94
34. Uhlmann F, Wernic D, Poupart MA, et al. Cleavage of cohesin by the CD clan protease separin triggers anaphase in yeast. Cell 2000 Oct 27; 103: 375-86
35. Salvesen GS. Caspases and apoptosis. Essays Biochem 2002; 38: 9-19
36. Lecaille F, Kaleta J, Bromme D. Human and parasitic papain-like cysteine proteases: their role in physiology and pathology and recent developments in inhibitor design. Chem Rev 2002 Dec; 102: 4459-88
37. Faleiro L, Kobayashi R, Fearnhead H, et al. Multiple species of CPP32 and Mch2 are the major active caspases present in apoptotic cells. EMBO J 1997 May 1; 16: 2271-81
38. Mason RW, Wilcox D, Wikstrom P, et al. The identification of active forms of cysteine proteinases in Kirsten-virus-transformed mouse fibroblasts by use of a specific radiolabelled inhibitor. Biochem J 1989 Jan 1; 257: 125-9
39. Joyce JA, Baruch A, Chehade K, et al. Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell 2004 May; 5: 443-53
40. Baruch A, Greenbaum D, Levy ET, et al. Defining a link between gap junction communication, proteolysis, and cataract formation. J Biol Chem 2001 Aug 3; 276: 28999-9006
41. Yasothornsrikul S, Greenbaum D, Medzihradszky KF, et al. CathepsinL in secretory vesicles functions as a prohormone-processing enzyme for production of the enkephalin peptide neurotransmitter. Proc Natl Acad Sci U S A 2003 Aug 5; 100: 9590-5
42. Greenbaum DC, Baruch A, Grainger M, et al. A role for the protease falcipain 1 in host cell invasion by the human malaria parasite. Science 2002 Dec 6; 298: 2002-6
43. Oleksy A, Golonka E, Banbula A, et al. Growth phase-dependent production of a cell wall-associated elastinolytic cysteine proteinase by Staphylococcus epidermidis. Biol Chem 2004 Jun; 385: 525-35
44. van der Hoorn RA, Leeuwenburgh MA, Bogyo M, et al. Activity profiling of papain-like cysteine proteases in plants. Plant Physiol 2004 Jul; 135: 1170-8
45. Boatright KM, Renatus M, Scott FL, et al. A unified model for apical caspase activation. Mol Cell 2003 Feb; 11: 529-41
46. Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature 2001 Feb 15; 409: 860-921
47. Jessani N, Liu Y, Humphrey M, et al. Enzyme activity profiles of the secreted and membrane proteome that depict cancer cell invasiveness. Proc Natl Acad Sci U S A 2002 Aug 6; 99: 10335-40
48. Overall CM, Lopez-Otin C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer 2002 Sep; 2: 657-72
49. Puente XS, Sanchez LM, Overall CM, et al. Human and mouse proteases: a comparative genomic approach. Nat Rev Genet 2003 Jul; 4: 544-58
50. Chang C, Werb Z. The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol 2001 Nov; 11: S37-43
51. Turner AJ, Isaac RE, Coates D. The neprilysin (NEP) family of zinc metalloendopeptidases: genomics and function. Bioessays 2001 Mar; 23: 261-9
52. Garcia-Echeverria C, Traxler P, Evans DB. ATP site-directed competitive and irreversible inhibitors of protein kinases. Med Res Rev 2000 Jan; 20: 28-57
53. Colman RF. Affinity labeling of purine nucleotide sites in proteins. Annu Rev Biochem 1983; 52: 67-91
54. Wymann MP, Bulgarelli-Leva G, Zvelebil MJ, et al. Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction. Mol Cell Biol 1996 Apr; 16: 1722-33
55. Mustelin T, Feng GS, Bottini N, et al. Protein tyrosine phosphatases. Front Biosci 2002 Jan 1; 7: d85-142
56. Ross DT, Scherf U, Eisen MB, et al. Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 2000 Mar; 24: 227-35
57. Konecny G, Untch M, Pihan A, et al. Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer. Clin Cancer Res 2001 Jun; 7: 1743-9
58. Kanitakis J, Narvaez D, Claudy A. Differential expression of the CD10 antigen (neutral endopeptidase) in primary versus metastatic malignant melanomas of the skin. Melanoma Res 2002 Jun; 12: 241-4
59. Galardy RE, Grobelny D, Foellmer HG, et al. Inhibition of angiogenesis by the matrix metalloprotease inhibitor N-[R-2-(hydroxamidocarbonymethyl)-4- methylpentanoyl)]L-tryptophan methylamide. Cancer Res 1994 Sep 1; 54: 4715-8
60. Grobelny D, Poncz L, Galardy RE. Inhibition of human skin fibroblast collagenase, thermolysin, and Pseudomonas aeruginosa elastase by peptide hydroxamic acids. Biochemistry 1992 Aug 11; 31: 7152-4
61. Solorzano CC, Ksontini R, Pruitt JH, et al. A matrix metalloproteinase inhibitor prevents processing of tumor necrosis factor alpha (TNF alpha) and abrogates endotoxin-induced lethality. Shock 1997 Jun; 7: 427-31
62. Baruch A, Jeffery DA, Bogyo M. Enzyme activity: it's all aboutimage. Trends Cell Biol 2004 Jan; 14: 29-35
63. Gurtu V, Kain SR, Zhang G. Fluorometric and colorimetric detection of caspase activity associated with apoptosis. Anal Biochem 1997 Aug 15; 251: 98-102
64. Packard BZ, Toptygin DD, Komoriya A, et al. Design of profluorescent protease substrates guided by exciton theory. Methods Enzymol 1997; 278: 15-23
65. Komoriya A, Packard BZ, Brown MJ, et al. Assessment of caspase activities in intact apoptotic thymocytes using cell-permeable fluorogenic caspase substrates. J Exp Med 2000 Jun 5; 191: 1819-28
66. Hirata H, Takahashi A, Kobayashi S, et al. Caspases are activated in a branched protease cascade and control distinct downstream processes in Fas-induced apoptosis. J Exp Med 1998 Feb 16; 187: 587-600
67. Speers AE, Adam GC, Cravatt BF. Activity-based protein profiling in vivo using a copper(i)-catalyzed azide-alkyne[3 + 2] cycloaddition. J Am Chem Soc 2003 Apr 23; 125: 4686-7
68. Speers AE, Cravatt BF. Profiling enzyme activities in vivo using click chemistry methods. Chem Biol 2004 Apr; 11: 535-46
69. Ovaa H, van Swieten PF, Kessler BM, et al. Chemistry in living cells: detection of active proteasomes by a two-step labeling strategy. Angew Chem Int Ed Engl 2003 Aug 11; 42: 3626-9
70. Hopkins AL, Groom CR. The druggable genome. Nat Rev Drug Discov 2002 Sep; 1: 727-30
71. Drews J. Drug discovery: a historical perspective. Science 2000 Mar 17; 287: 1960-4
72. Sordella R, Bell DW, Haber DA, et al. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004; 305: 1163-7
73. Leung D, Hardouin C, Boger DL, et al. Discovering potent and selective reversible inhibitors of enzymes in complex proteomes. Nat Biotechnol 2003 Jun; 21: 687-91